# US 2019/0169316 A1 · Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169316 A1
- Document ID: US20190169316A1
- Status: Published application
- Kind: A1
- Application number: 16/271,735
- Filed: 2019-02-08
- Published: 2019-06-06
- Earliest claimed: 2005-10-26
- Assignees: CyDex Pharmaceuticals, Inc.
- Applicants: CyDex Pharmaceuticals, Inc.
- Inventors: James D. Pipkin; Gerold L. Mosher; Douglas B. Hecker
- Web page: https://patentgrep.com/patent/US20190169316A1

## CPC

- C08B 37/0012: {Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/205: {Polysaccharides, e.g. alginate, gums; Cyclodextrin}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K 31/724: Cyclodextrins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- B01D 1/18: to obtain dry solids (B01D1/24 takes precedence)
- B01J 8/24: according to "fluidised-bed" technique (B01J8/20 takes precedence)
- C07H 5/04: to nitrogen
- C08B 37/0015: {Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes}
- C08L 5/16: Cyclodextrin; Derivatives thereof
- Y10T 428/2982: Particulate matter [e.g., sphere, flake, etc.]
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAECD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.

## Claims

### Claim 1

A process for preparing a particulate sulfoalkyl ether composition, the process comprising:
a. providing an aqueous liquid feed comprising water and sulfoalkyl ether cyclodextrin; and
b. subjecting the liquid feed to a combination fluidized bed spray drying process whereby the sulfoalkyl ether cyclodextrin is dried to below the point of deliquescence to form a particulate sulfoalkyl ether cyclodextrin composition comprising agglomerated particles and having a CARR's index of less than or equal to 24%, a bulk density in the range of 0.55 to 0.66 g/cm3, and a tapped density in the range of 0.66 to 0.75 g/cm3,
wherein the fluidized bed spray drying process comprises:
providing an aqueous liquid feed comprising a liquid carrier and sulfoalkyl ether cyclodextrin;
providing in a drying chamber a fluidized bed of sulfoalkyl ether cyclodextrin particles having a first mean particle diameter, wherein the bed is fluidized with a stream of heated gas flowing in a first direction;
atomizing the liquid feed with an atomizer onto particles in the drying chamber to form a particulate sulfoalkyl ether cyclodextrin composition comprising agglomerated particles having a greater second mean particle diameter, wherein the atomization is conducted in a second direction and a majority of the liquid carrier has been removed from the particulate composition; and
collecting the particulate composition to form the sulfoalkyl ether cyclodextrin composition; and
wherein the sulfoalkyl ether cyclodextrin composition, wherein the SAE-CD is a compound of the Formula 1, or a combination thereof:
wherein: n is 4, 5 or 6;
R1, R2, R3, R4, R5, R6, R7, R8 and R9 are each, independently, —O— or a —O—(C2-C6 alkylene)-SO3− group, wherein at least one of R1 to R9 is independently a —O—(C2-C6 alkylene)-SO3− group, a —O—(CH2)mSO3− group wherein m is 2 to 6, —OCH2CH2CH2SO3−, or —OCH2CH2CH2CH2SO3−; and
Si, S2, S3, S4, S5, S6, S7, S8 and S9 are each, independently, a pharmaceutically acceptable cation.